NICE now recommends Crysvita to treat X-linked hypophosphatemia.- Kyowa Hakko Kirin + Ultragenyx.
The National Institute for Health and Care Excellence (NICE) has now recommended Crysvita (burosumab) from Kyowa Hakko Kirin within its EU marketing authorization, for treating X-linked hypophosphatemia (XLH) in children and young people with growing bones in England and Wales after the company agreed to a price reduction. XLH is an inherited genetic disorder that causes low levels of phosphate in the blood. This leads to soft, weak bones, which can result in life-long physical disabilities and pain. Children with the condition usually have bowed or bent legs, short stature, bone pain and delayed walking, and may also have dental problems and hearing loss.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins